

UK University Heart and Vascular Center

Advantages Of Supera VMI Stent For Complex FemPop Occlusive Lesions: Technical Tips: They Work Even In The Subintimal Position

Prof. Dr. Erwin Blessing
Veith Symposium
New York City, November 21st, 2024

Universitätsklinikum Hamburg Eppendorf

UK Prof. Dr. Erwin Blessing Veith Symposium 2

Financial Disclosures

Speakers Honorarium, Advisory Board:

Medtronic, Abbott Medical, B. Braun, Terumo, Cardinal Health,
Boston Scientific, Biotronik, Shockwave Medical

UK Prof. Dr. Erwin Blessing Veith Symposium 3

Supera™ - Advantages

- Strength—its high resistance to compression¹⁷**
- Low chronic outward force against vessel walls¹⁸**
- High flexibility,¹⁹ which allows for fracture resistance²**

0 FRACTURES AT 1 YEAR ACROSS ALL STUDIES^{1,2,3,4,5,6,7,8}

UK Prof. Dr. Erwin Blessing Veith Symposium 4

Supera™ - Challenges

THREE KEYS FOR OPTIMAL STENT DEPLOYMENT

UK Prof. Dr. Erwin Blessing Veith Symposium 5

Lesion preparation prior implantation: why is it so important?

High patency rates are demonstrated in cases where appropriate implant selection, vessel preparation, and deployment technique are used.

Lesion Category	Preparation	Primary Patency (%)	p-value
Moderate (21-40%)	Compressed	83.3%	p<0.005
Minimal (11-20%)	Compressed	81.8%	p<0.268
Nominal (± 10%)	Nominal	90.5%	
Minimal (11-20%)	Elongated	73.7%	p<0.026
Moderate (21-40%)	Elongated	74.4%	p<0.026
Severe (40%)	Elongated	57.7%	p<0.001

UK Prof. Dr. Erwin Blessing Veith Symposium 6

Supera™: Clinical data (Superb Trial)

(n: 264)

Lesion length: 7.8 cm
TASC A or B: 94.3 %
CTO: 24.6 %
RC 2 or 3: 94.7 %
Ca++ severe.: 44.7 %

Cath Card Vasc Interv. 2017. Garcia et al.

UK Prof. Dr. Erwin Blessing VAS Symposium 7

Do they also work in the subintimal position?

UK Prof. Dr. Erwin Blessing VAS Symposium 8

Case 1

UK Prof. Dr. Erwin Blessing VAS Symposium 9

Case 2

BeBack™

Supera™
PRESTO
(sheathless)

UK Prof. Dr. Erwin Blessing VAS Symposium 10

Case 2

26 months
follow up

UK Prof. Dr. Erwin Blessing VAS Symposium 11

Case 3

Blessing, VASA 2021

UK Prof. Dr. Erwin Blessing VAS Symposium 12

Case 3

Blessing, VASA 2021



UK Prof. Dr. Erwin Blessing VASA Symposium 14




Supera™ : Clinical data subintimal space (Supersub II-Study)

Received 28 September 2023 | Revised 4 February 2024 | Accepted 07 March 2024
DOI: 10.1002/cd.11028

ORIGINAL ARTICLE · CLINICAL SCIENCE WILEY

A multicenter prospective observational study appraising the effectiveness of the Supera stent after subintimal recanalization of femoro-popliteal artery occlusion: The SUPERSUB II study

Luis Mariano Palena MD^{1,2} | Giacomo Isernia MD³ | Gianbattista Parlani MD³ | Pierfrancesco Veroux MD⁴ | Ilaria Ficarelli MD⁵ | Arian Frascheri MD⁶ | Aldo Pischedda MD⁷ | Lorenzo Patrone MD⁸ | Carlo Patrizio Dionisi MD⁹ | Roberto Cianni MD¹⁰ | Flavio Ajroldi MD¹¹ | Pietro Landino MD¹² | Andrés Kleban MD¹³ | Pietro Filardi MD¹⁴ | Giovanni Frascacua MD¹⁵ | Pier Luigi Antignani MD¹⁶ | Enrico De Rose MSc¹⁷ | Albert Valls MSc¹⁷ | Giuseppe Blondi-Zoccal MD^{18,19} | Marco Manzi MD¹



UK Prof. Dr. Erwin Blessing VASA Symposium 18

Conclusions

- Proper lesion preparation mandatory prior implantation of Supera™ stents
- Robust clinical data from multiple single arm studies/registries also in very complex lesions
- They seem to work quite well, even in the subintimal space
- Lack of level 1 evidence (no head to head comparison trials)